Affordable Access

Secnidazole. A 5-nitroimidazole derivative with a long half-life.

Publication Date
  • Research Article
  • Medicine
  • Pharmacology


The therapeutic activity of a single 2 g dose of secnidazole was studied in patients with urogenital trichomoniasis. In 140 patients, 97% were cured and the drug was well tolerated. In the laboratory, tests on sensitivity were made and the minimal inhibitory concentration (MIC) and the minimal trichomonacidal concentration (MTC) were determined on cultures that had recently been isolated at the clinic, and the pharmacokinetic properties of secnidazole in man were compared with those of tinidazole. The therapeutic efficacy of all the metronidazole derivatives was reviewed and a single-dose treatment is recommended. Therapeutic and prophylactic treatment is achieved by products with a long half-life. Secnidazole, with a half-life of 14.3 +/- 1.3 h (women) and 20.2 +/- 3.1 h (men), is particularly suitable for this type of treatment.

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times

More articles like this

Secnidazole. A 5-nitroimidazole derivative with a...

on The British journal of venerea... April 1978

Secnidazole--a nitroimidazole with a prolonged ser...

on The Journal of antimicrobial c... July 1979

The half-life of V50

on Nuclear Physics Jan 01, 1962

Artemisinin derivatives with long elimination half...

on The Journal of pharmacy and ph... October 2008
More articles like this..